Aclaris Therapeutics, Inc. (ACRS) has a negative trailing P/E of -7.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -13.52%.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -12.1 | -0.12 | 3.43 | 0.00 | - |
| 2017 | -10.1 | -1.20 | 3.08 | 411.77 | - |
| 2018 | -1.8 | -0.03 | 1.13 | 24.10 | - |
| 2019 | -0.5 | 0.03 | 1.12 | 18.48 | - |
| 2020 | -5.4 | 0.08 | 7.31 | 42.46 | - |
| 2021 | -9.1 | -0.27 | 4.18 | 122.00 | - |
| 2022 | -11.8 | 0.70 | 5.20 | 34.52 | - |
| 2023 | -0.8 | 0.18 | 0.47 | 2.35 | - |
| 2024 | -1.5 | -0.04 | 1.23 | 10.24 | - |
| 2025 | -5.7 | 0.08 | 3.58 | 47.18 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.25 | $0.00 | $-48.08M | - |
| 2017 | $-2.44 | $1.68M | $-68.52M | -4071.5% |
| 2018 | $-4.03 | $10.09M | $-132.74M | -1315.4% |
| 2019 | $-3.46 | $4.23M | $-142.85M | -3379.5% |
| 2020 | $-1.20 | $6.48M | $-51.15M | -789.2% |
| 2021 | $-2.01 | $6.76M | $-114.28M | -1690.3% |
| 2022 | $-1.36 | $29.75M | $-88.66M | -298% |
| 2023 | $-1.27 | $31.25M | $-88.48M | -283.1% |
| 2024 | $-1.71 | $18.72M | $-132.07M | -705.5% |
| 2025 | $-0.53 | $7.83M | $-64.92M | -829.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.63 | $-0.71 – $-0.49 | $4.52M | $742.75K – $8.25M | 5 |
| 2027 | $-0.66 | $-0.81 – $-0.47 | $5.25M | $804.23K – $10.72M | 6 |
| 2028 | $-0.76 | $-1.03 – $-0.33 | $6.2M | $981.6K – $12M | 5 |
| 2029 | $-0.76 | $-1.68 – $0.07 | $40.2M | $6.37M – $77.84M | 1 |
| 2030 | $-0.58 | $-1.28 – $0.05 | $130.2M | $20.63M – $252.14M | 1 |
